Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;22(2):864.
doi: 10.3892/etm.2021.10296. Epub 2021 Jun 11.

Renal replacement therapy in cancer patients with acute kidney injury (Review)

Mircea Lupuşoru  1 , Gabriela Lupuşoru  2   3 , Ioana Ailincăi  2 , Georgiana Frățilă  2 , Andreea Andronesi  2   3 , Elena Micu  2   3 , Mihaela Banu  4 , Radu Costea  5 , Gener Ismail  1   2
Affiliations
Review

Renal replacement therapy in cancer patients with acute kidney injury (Review)

Mircea Lupuşoru et al. Exp Ther Med. 2021 Aug.

Abstract

Cancer patients are at high risk for developing acute kidney injury (AKI), which is associated with increased morbidity and mortality in these patients. Despite the progress made in understanding the pathogenic mechanisms and etiology of AKI in these patients, the main prevention consists of avoiding medication and nephrotoxic agents such as non-steroidal anti-inflammatory drugs, contrast agents used in medical imaging and modulation of chemotherapy regimens; when prophylactic measures are overcome and renal impairment becomes unresponsive to treatment, renal replacement therapy (RRT) is required. There are several methods of RRT that can be utilized for patients with malignancies and acute renal impairment; the choice of treatment being based on the patient characteristics. The aim of this article is to review the literature data regarding the epidemiology and management of AKI in cancer patients, the extracorporeal techniques used, choice of the appropriate therapy and the optimal time of initiation, and also the dose-prognosis relationship.

Keywords: acute kidney injury; cancer; continuous renal replacement therapy; hybrid therapy; intermittent renal replacement therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Schematic representation of the MCO hemodialyzer. MCO, medium cut-off.
See this image and copyright information in PMC

References

    1. Finkel K, Perazella MA, Cohen E. Acute kidney injury-Incidence, Pathogenesis and Outcomes. In: Onco-Nephrology. 1st edition. Elsevier, Amsterdam, pp270-274, 2019.
    1. Bratu OG, Cherciu AI, Bumbu A, Lupu S, Marcu DR, Ionita-Radu F, Manea M, Furau C, Diaconu CC, Mischianu DL. Retroperitoneal tumours-treatment and prognosis of tumour recurrence. Rev Chim. 2019;70:190–194.
    1. Marcu DR, Ionita-Radu F, Iorga LD, Manea M, Socea B, Scarneciu I, Isvoranu G, Costache R, Diaconu CC, Bratu OG. Vascular involvement in primary retroperitoneal tumors. Rev Chim. 2019;70:445–448.
    1. Draghici T, Negreanu L, Bratu OG, Stoian AP, Socea B, Neagu TP, Stanescu AM, Manuc D, Diaconu CC. Paraneoplastic syndromes in digestive tumors: A review. Rom Biotechnol Lett. 2019;24:813–819.
    1. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009;4:1275–1283. doi: 10.2215/CJN.02050309. - DOI - PubMed